Last Updated: 18 Sep 2024
Executive Summary
Reneo Pharmaceuticals Inc. (RPHM) is a clinical-stage pharmaceutical company focused on developing therapies for rare genetic mitochondrial diseases. Despite promising research and development efforts, the company faces challenges in generating revenue and profitability. Its stock price has declined significantly in recent years, currently trading at $1.39. While analysts maintain a "Hold" rating, the company's long-term prospects remain uncertain.
Company Overview
Reneo Pharmaceuticals was founded in 2012 and is headquartered in San Diego, California. The company's lead pipeline candidate, REN001, is a small molecule inhibitor of the mitochondrial pyruvate carrier. REN001 is currently in Phase 2 clinical trials for the treatment of mitochondrial pyruvate carrier deficiency, a rare genetic disorder.
Fundamental Analysis
Revenue: Reneo Pharmaceuticals has yet to generate any revenue from its product pipeline.
EBITDA: The company's EBITDA loss for the trailing twelve months is $61.06 million.
EPS: The company's diluted EPS for the trailing twelve months is -$1.68.
Book Value: The company's book value per share is $2.3.
Return on Assets (TTM): The company's return on assets for the trailing twelve months is -0.337.
Return on Equity (TTM): The company's return on equity for the trailing twelve months is -0.54.
Technical Analysis
52-Week High: $9.21
52-Week Low: $0.98
50-Day Moving Average: $1.468
200-Day Moving Average: $1.896
Beta: 0.201
The stock price has been trending downwards in recent months and is currently below its 50-day and 200-day moving averages. The beta of 0.201 indicates that the stock is less volatile than the overall market.
Short Term Outlook
In the short term, Reneo Pharmaceuticals faces challenges in meeting its clinical trial milestones and generating revenue. The company's stock price is likely to remain volatile and could decline further if it fails to meet expectations.
Long Term Outlook
The long-term outlook for Reneo Pharmaceuticals is uncertain. The company's success depends on the results of its clinical trials and its ability to commercialize its products. If REN001 proves to be effective and safe, it could generate significant revenue for the company. However, the company faces competition from other pharmaceutical companies developing treatments for mitochondrial diseases.
Analyst Recommendations
Analysts currently maintain a "Hold" rating on Reneo Pharmaceuticals. Three analysts recommend holding the stock, while none recommend buying or selling. The average analyst target price is $2.25.
